Best Price for Fingolimod HCl - Palonosetron Hydrochloride CAS 135729-62-3 Purity ≥99.0% API USP EP High Quality – Ruifu

Manufacturer with High Quality and Competitive Price
Commercial Supply Palonosetron Hydrochloride (CAS: 135729-62-3) Related Intermediates:
1,2,3,4-tetrahydro-naphthoic acid CAS: 1914-65-4
(S)-1,2,3,4-tetrahydro-naphthoic acid CAS: 85977-52-2
(R)-1,2,3,4-Tetrahedro-naphthoic acid CAS: 23357-47-3
(S)-3-Aminoquinuclidine dihydrochloride CAS: 119904-90-4
3-Quinuclidinone Hydrochloride CAS: 1193-65-3
1-Naphthoic acid CAS: 86-55-5
Palonosetron Hydrochloride CAS: 135729-62-3 API

Package: Bottle, Cardboard Drum, 25kg/Drum, or according to customer’s requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.

Manufacturer with High Quality and Competitive Price
Commercial Supply Palonosetron Hydrochloride (CAS: 135729-62-3) Related Intermediates:
1,2,3,4-tetrahydro-naphthoic acid CAS: 1914-65-4
(S)-1,2,3,4-tetrahydro-naphthoic acid CAS: 85977-52-2
(R)-1,2,3,4-Tetrahedro-naphthoic acid CAS: 23357-47-3
(S)-3-Aminoquinuclidine dihydrochloride CAS: 119904-90-4
3-Quinuclidinone Hydrochloride CAS: 1193-65-3
1-Naphthoic acid CAS: 86-55-5
Palonosetron Hydrochloride CAS: 135729-62-3 API

Palonosetron Hydrochloride CAS: 135729-62-3 is a drug to inhibit nausea and vomiting, which is a new type highly selective, high-affinity 5-HT3 receptor antagonist that can block the vomiting reflex center peripheral neurons presynaptic 5-HT. Receptor excitement directly affects the central nervous system in 5-HT. Impulse receptor excitement generated by the role of vagal afferent nerve after area, blocking the vagus nerve endings in the gut, preventing signals to 5-HT. Receptor trigger zone can reduce the incidence of nausea and vomiting. Central clinically for the treatment of acute severe emetogenic chemotherapy induced delayed nausea and vomiting. Because of its high curative effect, little side effect, long half-life (about 40 h), small dosage, and so on, it has attracted much attention.

With 1,2,3,4-tetrahydro-1-naphthoic acid as the starting material, the split, amination, reduction, cyclization, salt of palonosetron hydrochloride granisetron. Clinical studies showed that palonosetron can be used safely with corticosteroids, analgesics, antiemetics, antispasmodics and anticholinergic drugsas the starting material, the split, amination, reduction, cyclization, salt of palonosetron hydrochloride granisetron.

The most common adverse effects are headache, which occurs in 4–11% of patients, and constipation in up to 6% of patients. In less than 1% of patients, other gastrointestinal disorders occur, as well as sleeplessness, first-and second-degree atrioventricular block, muscle pain and shortness of breath. Palonosetron is similarly well tolerated as other setrons, and slightly less than placebo.